CEO
K36 Therapeutics, Inc.
K36 is developing KTX-1001, a first-in-class selective inhibitor targeting the histone methyltransferase MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t(4;14) translocation. This targeted therapy aims to provide a specific treatment option for patients with this genetic alteration, addressing a significant unmet medical need in cancer care.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$100MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
A subset of multiple myeloma patients, approximately 20%, exhibit overexpression of the histone methyltransferase MMSET due to the t(4;14) translocation, driving tumor growth and presenting a specific therapeutic challenge. Current treatment options do not directly target this genetic alteration.
Solution
K36 is developing KTX-1001, a first-in-class selective inhibitor of MMSET designed to target the underlying cause of cancer in multiple myeloma patients with the t(4;14) translocation. By specifically inhibiting MMSET, KTX-1001 aims to modulate oncogenic pathways and provide a targeted therapeutic approach for this patient population. KTX-1001 represents the first therapeutic agent entering clinical trials that directly addresses MMSET overexpression.
Target Audience
The primary target audience is multiple myeloma patients who have the t(4;14) translocation and overexpress the MMSET protein.
Features
- Selective inhibition of the histone methyltransferase MMSET
- Designed for multiple myeloma patients with t(4;14) translocation
- First-in-class therapeutic agent directly targeting MMSET overexpression
- Aims to modulate oncogenic pathways